News

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about the long-term safety of Amgen’s rocatinlimab for AD, the shared genetic backgrounds of cardiovascular diseases and psoriasis, the availability of LEO Pharma's delgocitinib cream, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Cigna’s removal of restrictions on home phototherapy, following a similar decision by Elevance Health, expands access to more than 66 million Americans.

Dermatologists and hairstylists unite to address scalp health, cultural practices, and patient care at the Science of Skin & Scalp Studio event.

Explore the complex genetic links between psoriasis and cardiovascular diseases, highlighting the IL-23 and IL-17 pathways' role in health risks.

Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.

Darker skin tones face higher risks of photosensitivity and thermal burns during dual-wavelength laser therapy, highlighting the need for tailored treatment approaches.

New guidelines enhance understanding and treatment of genital psoriasis, addressing its psychological impact and improving patient-provider communication.

Discover how medium-to-deep chemical peels effectively treat refractory melasma, enhancing skin tone and quality with tailored approaches.

Upadacitinib maintained high EASI and itch response rates through nearly 3 years of treatment.

Phase 3 trials demonstrated that icotrokinra met all primary and co-primary endpoints, including PASI 90 and IGA 0/1 responses.

Explore innovative treatments for seborrheic dermatitis, including roflumilast foam, and learn about effective patient-centered care strategies.

HS management is shifting toward earlier diagnosis and intervention to prevent long-term scarring and disability.

In the latest Cutaneous Connection podcast episode, Renata Block, DMSc, MMS, PA-C, and Isabelle Thibau, MPH, discuss the National Eczema Association's EczemaWise app and how it can be used by both clinicians and patients.

Dermalogica's PRO Pen Microneedling System gains FDA clearance, revolutionizing non-invasive skin treatments with advanced technology and customizable options.

Discover the benefits of RetaXome therapy for sensitive skin and its potential in skin care routines.

The expanded voluntary recall is due to the potential microbial contamination of Burkholderia cepacia complex.

Amlitelimab shows promising phase 3 results in treating atopic dermatitis, achieving significant skin clearance and potential for infrequent dosing.

The new product expands Obagi Medical’s portfolio beyond skin care into injectables.

Alopecia areata treatment advances with targeted therapies, improving patient outcomes and access while addressing the emotional impact of hair loss.

This review of the latest dermatologic studies highlights new research on novel image fusion for tongue SCC, persistent nodules following HA fillers, rice bran extract for wound healing, and more.

Isotretinoin significantly reduces inflammatory cytokines IL-8, IL-36, and TWEAK in acne patients, promoting long-term acne remission and healing.

New insights reveal psoriasis patients' challenges with family planning and pregnancy, highlighting the need for better information and support from healthcare providers.

Phase 3 topline results reveal rocatinlimab's promising safety and efficacy for moderate to severe AD, targeting the OX40 receptor.

Forty percent of participants achieved at least a 75% reduction in facial vitiligo scores.

In part 3 of this Case-Based Roundtable supplement, Seemal Desai, MD, FAAD; Ted Lain, MD, MBA, FAAD; and Pearl Grimes, MD, FAAD, discuss real-world vitiligo scenarios, offering diagnostic insights, therapeutic strategies, and practical pearls from their own experiences.

Medicus Pharma has initiated a phase 2 trial in the UAE for a non-invasive BCC treatment, aiming to revolutionize skin cancer care.

LEO Pharma's delgocitinib cream for chronic hand eczema is now available to prescribe in the US.